Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$0.39
>-$0.01(-0.97%)
At close: 4:00 PM EDT
$0.39
>-$0.01(-0.97%)
Day’s Range― - ―
52-Week Range$0.33 - $2.88
Previous CloseN/A
Volume63.62K
Average Volume (3M)211.22K
Market Cap
$10.65M
Enterprise Value$40.95
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$20.23M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding31,144,754
10 Day Avg. Volume239,900
30 Day Avg. Volume211,222
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$58.00K
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower absolute debt reduces scheduled financing pressure and may improve financial flexibility relative to prior periods. However, the benefit is constrained by negative equity, asset depletion, and continuing cash consumption.
Moderating Cash BurnThe reduced operating cash outflow indicates some progress in controlling cash usage. If sustained, this could extend the company’s operating runway, although the current burn remains substantial and does not yet demonstrate financial self-sufficiency.
Potential Strategic TransactionThe proposed merger and contingent value right could provide shareholders with milestone-linked exposure to SENTI-202 while supporting a broader strategic transition. The potential benefit is meaningful but depends on transaction approval and future regulatory and sales milestones.
Bears Say
Minimal Revenue ScaleRevenue remains too small and inconsistent to absorb the company’s operating costs or demonstrate commercial traction. Until partnered programs produce more reliable funding or products reach approval, the business remains dependent on external financing and development milestones.
Persistent Losses And Cash BurnLarge recurring losses are translating directly into substantial cash consumption, leaving limited evidence of operating leverage. Continued spending on clinical development without materially higher revenue increases funding needs and may dilute existing shareholders.
Negative Equity And Asset ErosionNegative equity and the sharp decline in total assets indicate that prior resources have been substantially depleted. This weakens financial resilience, limits flexibility in funding development, and raises dependence on new financing or strategic transactions.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $0.33 and its highest was $2.88 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $10.65M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 69 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Overvalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 31,144,754 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.14 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Technical Analysis
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
0.11% Other Institutional Investors
95.06% Public Companies and
Individual Investors